AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02307669 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines.
Study NCT00304265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)
Description: 0.5 mL, Intramuscular
Study NCT01820078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITMHA
Description: Given intrathecally (IT).
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase Erwinia Chrysanthemi
Description: Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
Study NCT01820078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparator Arm
Description: Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
Study NCT01820078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comparator Arm
Description: Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Taken PO or NG.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT03104621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride (BAK)
Description: Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
Study NCT03104621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.0015% tafluprost
Description: Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
Study NCT02406794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular taping
Description: The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
Study NCT02166034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: garden intervention
Description: The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
Study NCT01622608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vaccine Information Kiosk
Description: The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
Study NCT01119807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous access during OHCA
Description: First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
Study NCT01119807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Humeral IO insertion
Description: First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
Study NCT01119807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIbial IO insertion
Description: First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
Study NCT03382431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC786
Description: Repeat doses
Study NCT03382431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/vehicle
Description: Repeat doses
Study NCT00444236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium
Description: nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
Study NCT00444236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo for active drug
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO or NG.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IM or PO.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Leucovorin rescue PO or IV.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
Study NCT02553460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV.
Study NCT02044523 — intervention group
Intervention type: DEVICE
Intervention: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Description: Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
Study NCT00521833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification and intraocular lens implantation
Description: clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
Study NCT02847117 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mastiha
Description: The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
Study NCT01026636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Study NCT01094405 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Epstein-Barr Virus (EBV) Vaccine
Study NCT04705922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Capsule
Description: TT-00420 capsule formulation, administered orally
Study NCT04705922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420 Tablet
Description: TT-00420 tablet formulation, administered orally
Study NCT00212056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANP(hANP)
Description: 0∙025 μg/kg per min for 3 days(intravenous)
Study NCT00212056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo
Study NCT03384069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Cognitive Behavioral Therapy (CBT)
Description: The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
Study NCT03384069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Cognitive Behavioral Therapy (CBT)
Description: Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
Study NCT04036630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS)
Description: The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition.
Study NCT04036630 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS)
Description: The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition.
Study NCT04036630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial alternating current stimulation (tACS)
Description: The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition.
Study NCT04036630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)
Description: TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple.
Study NCT04036630 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)
Description: TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple.
Study NCT04426045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: A curvilinear 2-5MHz ultrasound probe will be initially placed in a transverse plane over the anterior superior iliac spine and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the iliopubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A 22-gauge, 80-mm needle will be inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. A total volume of 20 ml of ropivacaine 0.2% will be injected.
Study NCT04426045 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-inguinal fascia iliaca compartment block
Description: A linear 6-13-MHz ultrasound probe will be placed in the sagittal plane to obtain an image of the anterior superior iliac spine. The fascia iliaca and sartorius, iliopsoas, and oblique internal muscles will be identified by sliding the probe medially. After identifying the bow-tie sign formed by the muscle fascias, a 22-gauge, 80-mm needle will be introduced 1 cm cephalad to the inguinal ligament. Using an in-plane approach, the fascia iliaca will be penetrated and hydrodissected, separating the fascia iliaca from the iliac muscle. A total volume of 30 ml of ropivacaine 0.2% will be injected.
Study NCT06153641 — intervention group
Intervention type: OTHER
Intervention: N/A-Observational Study
Description: N/A-Observational Study
Study NCT00369824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra TM
Description: One dose of vaccine administered intramuscularly
Study NCT01641913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Absorbable sugars
Description: Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
Study NCT03083119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule
Description: Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
Study NCT03083119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
Study NCT05105646 — intervention group
Intervention type: PROCEDURE
Intervention: Knee Arthroplasty, knee revision arthoplasty
Description: Primary knee arthroplasty (e.g., total, unicondylar and patellofemoral)
Study NCT03776890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DeStress for Health Program
Description: The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
Study NCT01714882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management & Resiliency Training
Description: The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
Study NCT01714882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management DVD
Description: The couples in this group will receive a Mayo Clinic Stress Management DVD.
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 single dose
Description: Safety and tolerability of single escalating doses
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo single dose
Description: Safety and tolerability of single escalating doses
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162: 7 day repeat dose
Description: Safety and tolerability of a repeat dose
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo: 7 day repeat dose
Description: Safety and tolerability of a repeat dose
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses
Study NCT01970618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1162 matching placebo: 14 day repeat dose
Description: Safety and tolerability of repeat escalating doses
Study NCT03034681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy technique: TENS
Study NCT03034681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy technique: Vojta Therapy
Study NCT00442117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
Study NCT01908621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF (filgrastim)
Study NCT01908621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine arabinoside + G-CSF (filgrastim)
Study NCT03021434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Community and household water safety education sessions
Description: Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
Study NCT03021434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community and household water safety education sessions
Description: Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
Study NCT03021434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household-specific water quality information
Description: Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
Study NCT03021434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-cost microbiological water test kits
Description: Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
Study NCT01672021 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET/MRI
Description: PET/MRI
Study NCT00649376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine Tablets 180 mg
Description: 180mg, single dose fasting
Study NCT00649376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra® Tablets 180 mg
Description: 180mg, single dose fasting
Study NCT02211976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study NCT02211976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeticone